🍪 TalkPeptides uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
Forums›Public Square›Started this morning and already overthinking everything › Page 2

Started this morning and already overthinking everything

hannah_MT Sat, Jan 3, 2026 at 12:20 PM 13 replies 1,158 viewsPage 2 of 3
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Jan 3, 2026 at 6:48 PM#6
Dr.AddMedPHL said:
Read four things before the headline number.

Pushing back on Dr.AddMedPHL here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

28 23NurseKim_ATL, paul_denver, TinaHashiRN and 25 others
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Jan 3, 2026 at 9:20 PM#7
I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].

The NNT was 8, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.

27 22DoseLogDan, SleepFixSam, PurityPaulOR and 24 others
Reply Quote Save Share Report
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Jan 3, 2026 at 11:52 PM#8
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

26 21tommy_boulder, hyun_seoul, jim_asheville and 23 others
Reply Quote Save Share Report

PeptideDetective — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Jan 4, 2026 at 2:24 AM#9

One thing that is still open after josh_phd_bmore’s answer:

How would you tell the difference between that and the alternative explanation?

25 20marco_milano, pam_columbus, nick_SD_fit and 22 others
Reply Quote Save Share Report
hannah_MT
OPNew Member
23
89
Feb 2026
Bozeman, MT
Jan 4, 2026 at 2:34 PM#10

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

45 20SleepFixSam, PurityPaulOR, MaxMetOK and 42 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register
Threads · Members · Forums
semaglutidetirzepatideretatrutidecompoundingbloodworkside effects